Table 1. Baseline patient demographics and disease characteristics (both FAS and SAF).
| Variable | Subgroup | CisPemBev, N=131 | CarPacBev, N=66 | P value |
|---|---|---|---|---|
| Age, median [range] | Years | 66.0 [36–74] | 67.0 [22–74] | 0.45 |
| Sex, n [%] | Male | 97 [74] | 47 [71] | 0.67 |
| Female | 34 [26] | 19 [29] | ||
| ECOG PS, n [%] | 0 | 68 [52] | 35 [53] | 0.88 |
| 1 | 63 [48] | 31 [47] | ||
| Disease stage, n [%] | IIIB | 14 [11] | 6 [9] | 0.88 |
| IV | 95 [73] | 50 [76] | ||
| Recurrence after surgery | 22 [17] | 10 [15] | ||
| Brain metastasis, n [%] | No | 109 [83] | 53 [80] | 0.61 |
| Yes | 22 [17] | 13 [20] | ||
| Tumor histology, n [%] | Adenocarcinoma | 128 [98] | 61 [92] | 0.08 |
| Large cell carcinoma | 1 [1] | 0 [0] | ||
| NSCLC | 2 [2] | 5 [8] | ||
| Smoking status, n [%] | No | 22 [17] | 12 [18] | 0.63 |
| Smoker | 36 [27] | 14 [21] | ||
| Previously smoked | 73 [56] | 40 [61] | ||
| ALK fusion gene, n [%] | − | 116 [89] | 58 [88] | 0.32 |
| +† | 2 [2] | 0 [0] | ||
| Unknown | 13 [10] | 8 [12] |
†, patients with ALK fusion gene-positive NSCLC were eligible if their ALK fusion gene status was unknown at study enrollment. ALK, anaplastic lymphoma kinase; CarPacBev, carboplatin + paclitaxel + bevacizumab; CisPemBev, cisplatin + pemetrexed + bevacizumab; ECOG PS, Eastern Cooperative Oncology Group performance status; FAS, full analysis set; NSCLC, non-small cell lung cancer; IQR, interquartile range; SAF, safety analysis set.